Spots Global Cancer Trial Database for donor lymphocyte infusion (dli)
Every month we try and update this database with for donor lymphocyte infusion (dli) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | NCT00499889 | Leukemia | Imatinib Mesyla... Fludarabine (Fl... Busulfan Antithymocyte G... Tacrolimus Methotrexate Donor lymphocyt... Stem Cell Trans... | - 70 Years | M.D. Anderson Cancer Center | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative | NCT00429143 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate M... Hematopoietic S... | 18 Years - | Thomas Jefferson University | |
| Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | NCT02566395 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Chronic Myeloge... Non-Hodgkin Lym... Hodgkin Lymphom... | Radiation Cyclophosphamid... Donor Lymphocyt... Haploidentical ... | 2 Years - 21 Years | Northwell Health | |
| Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation | NCT00984165 | Hodgkin's Lymph... Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | Single fraction... Donor Lymphocyt... Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | NCT01875237 | Leukemia Myeloma Myeloproliferat... | Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | NCT02566395 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Chronic Myeloge... Non-Hodgkin Lym... Hodgkin Lymphom... | Radiation Cyclophosphamid... Donor Lymphocyt... Haploidentical ... | 2 Years - 21 Years | Northwell Health | |
| Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | NCT01350245 | Acute Myeloid L... Myelodysplastic... Biphenotypic Le... Acute Lymphocyt... Chronic Myeloid... Chronic Lymphoc... Plasma Cell Neo... Lymphoma Hodgkin's Disea... Aplastic Anemia | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Mycophenolate M... Tacrolimus Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant | NCT01174082 | Myeloma | KLH Vaccine KLH-id Vaccine GM-CSF Apheresis Donor Lymphocyt... | 18 Years - 70 Years | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
